TY  - JOUR
AU  - Galan, Lucia
AU  - Gonzalez-Moreno, Juan
AU  - Martínez-Sesmero, José Manuel
AU  - Muñoz-Beamud, Francisco
AU  - Santos-Rubio, Maria Dolores
AU  - Tran, Diana
AU  - Lebeau, Paul
AU  - Stewart, Michelle
AU  - Mallaina, Pablo
AU  - Tarilonte, Patricia
AU  - Peral, Carmen
AU  - Rozenbaum, Mark H
PY  - 2021
DO  - 10.1080/14737167.2021.1900738
UR  - http://hdl.handle.net/10668/17355
T2  - Expert review of pharmacoeconomics & outcomes research
AB  - Background: Transthyretin amyloid polyneuropathy (ATTR-PN) is a fatal disease associated with substantial burden of illness. Three therapies are approved by the European Medicines Agency for the management of this rare disease. The aim of this study...
LA  - en
KW  - Hereditary amyloidosis
KW  - onpattro
KW  - rare disease
KW  - tegsedi
KW  - treatment cost analysis
KW  - vyndaqel
KW  - Amyloid Neuropathies, Familial
KW  - Benzoxazoles
KW  - Cost of Illness
KW  - Drug Costs
KW  - Health Care Costs
KW  - Hospitalization
KW  - Humans
KW  - Oligonucleotides
KW  - RNA, Small Interfering
KW  - Spain
TI  - Estimating the annual economic burden for the management of patients with transthyretin amyloid polyneuropathy in Spain.
TY  - research article
VL  - 21
ER  -